PP
AERI

PDT Partners’s Aerie Pharmaceuticals AERI Stock Holding History

PDT Partners’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-60,164
Closed -$910K – 971
2022
Q3 		$910K Sell
60,164
-96,873
-62% -$1.13M 0.14% 249
2022
Q2 		$1.18M Sell
157,037
-3,878
-2% -$27.3K 0.1% 341
2022
Q1 		$1.46M Buy
160,915
+120,498
+298% +$929K 0.13% 246
2021
Q4 		$284K Buy
+40,417
New +$423K 0.02% 686
2021
Q3 		– Sell
-93,136
Closed -$1.49M – 962
2021
Q2 		$1.49M Buy
93,136
+30,993
+50% +$532K 0.1% 305
2021
Q1 		$1.11M Sell
62,143
-1,867
-3% -$32.2K 0.08% 353
2020
Q4 		$865K Buy
+64,010
New +$773K 0.06% 354
2014
Q2 		– Sell
-10,734
Closed -$227K – 1714
2014
Q1 		$227K Buy
+10,734
New +$217K 0.01% 1200

PDT Partners's AERI Position: Q4 2022 in Review

PDT Partners sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 60,164 shares — an estimated $910K sold.

PDT Partners first reported a position in AERI in Q1 2014 and held it in 8 quarters. The position peaked at $1.49M in Q2 2021. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

  • PDT Partners reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • PDT Partners sold 60,164 Aerie Pharmaceuticals shares in Q4 2022, an estimated $910K.
  • PDT Partners first reported a position in Aerie Pharmaceuticals in Q1 2014 and held it in 8 quarters.
  • PDT Partners's Aerie Pharmaceuticals position peaked at $1.49M in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on PDT Partners's 13F filing for Q4 2022, filed 14 Feb 2023.